Covid19 Clinical Trial
Official title:
Home-based Exercise Training in COVID-19 Survivors: a Randomized Controlled Trial
The physical inactivity promoted by the patient's hospitalization, including those infected with the coronavirus, can lead to an important health impairment, including atrophy and loss of muscle function. Thus, a prospective study will be conducted to assess the effect of a home-based exercise training program on health outcomes and quality of life in COVID-19 survivors.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | September 30, 2022 |
Est. primary completion date | September 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 75 Years |
Eligibility | Inclusion Criteria: - Patients diagnosed with COVID-19 - Positive RT-PCR test and/or serology assay to detect IgG against SARS-CoV-2 in addition to acute symptomatology compatible with the disease - Admitted in intensive care unit Exclusion Criteria: - Cardiovascular disease - Resting dyspnea - Acute pulmonary embolism or pulmonary infarction - Deep venous thromboembolism - Uncontrolled visual or vestibular disorders - Pregnancy - Uncontrolled resting tachycardia - Uncontrolled hypertension - Uncontrolled Type II diabetes - Acute infections - Neurological disorders - Patients with chronic kidney disease who are in need of hemodialysis - Recent malignant neoplasm (<5 years) - Autoimmune diseases - Complex ventricular arrhythmias, atrial fibrillation or complete heart block - Transplant patients - Any physical disabilities that could hamper physical testing and exercise program |
Country | Name | City | State |
---|---|---|---|
Brazil | University of Sao Paulo | Sao Paulo |
Lead Sponsor | Collaborator |
---|---|
University of Sao Paulo |
Brazil,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline on quality of life assessed by the SF-36 health survey questionnaire at 16 weeks. | Higher score means better outcome. | Baseline and 16 weeks. | |
Secondary | Change from baseline on fatigue evaluated by the fatigue severity scale at 16 weeks. | Higher score means worse outcome. | Baseline and 16 weeks. | |
Secondary | Change from baseline on lipid profile at 16 weeks. | Total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides | Baseline and 16 weeks. | |
Secondary | Change from baseline on insulin sensitivity at 16 weeks. | Fasting serum concentrations of glucose and insulin. | Baseline and 16 weeks. | |
Secondary | Change from baseline on inflammatory cytokine IL-1 at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on inflammatory cytokine IL-1ra at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on inflammatory cytokine IL-6 at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on inflammatory cytokine IL-10 at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on inflammatory cytokine TNF-alpha at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on C-reactive Protein at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on Creatine Kinase at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on cardiopulmonary fitness assessed by a maximal exercise test at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on lean body mass assessed by Dual-energy absorptiometry at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline body fat assessed by Dual-energy absorptiometry at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on waist circumference at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on hip circumference at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on body weight at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on muscular strength assessed by handgrip test at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on muscular function assessed by Timed-Stand Test at 16 weesks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on muscular function assessed by Timed-Up and Go Test at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on anxiety symptoms assessed by Back Scale at 16 weeks. | Higher score means worse outcome. | Baseline and 16 weeks. | |
Secondary | Change from baseline on depression symptoms assessed by Back Scale at 16 weeks. | Higher score means worse outcome. | Baseline and 16 weeks. | |
Secondary | Change from baseline on functional status assessed by Post-COVID-19 Functional Status (PCFS) Scale at 16 weeks. | Higher score means worse outcome. | Baseline and 16 weeks. | |
Secondary | Change from baseline on physical activity levels evaluated by the International Physical Activity Questionnaire at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on resting blood pressure assessed by an automated device at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on fatigue assessed by Chalder scale at 16 weeks. | Higher score means worse outcome. | Baseline and 16 weeks. | |
Secondary | Change from baseline on heart rate variability assessed by heart rate monitor at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on inspiratory muscular strength assessed by power breathe at 16 weeks. | Baseline and 16 weeks. | ||
Secondary | Change from baseline on quality of life assessed by the SF-36 health survey questionnaire at one year. | Higher score means better outcome. | Baseline and one year. | |
Secondary | Change from baseline on fatigue evaluated by the fatigue severity scale at one year. | Higher score means worse outcome. | Baseline and one year. | |
Secondary | Change from baseline on fatigue assessed by Chalder scale at one year. | Higher score means worse outcome. | Baseline and one year. | |
Secondary | Change from baseline on functional status assessed by Post-COVID-19 Functional Status (PCFS) Scale at one year. | Higher score means worse outcome. | Baseline and one year. | |
Secondary | Change from baseline on muscular function assessed by Timed-Up and Go Test at one year. | Baseline and one year. | ||
Secondary | Change from baseline on muscular function assessed by Timed-Stand Test at one year. | Baseline and one year. | ||
Secondary | Change from baseline on muscular strength assessed by handgrip test at one year. | Baseline and one year. | ||
Secondary | Change from baseline on cardiopulmonary fitness assessed by a maximal exercise test at one year. | Baseline and one year. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |